Vastrax is the global development hub to support therapeutic innovators in the areas of neurovascular and peripheral products. The Vastrax team possesses a combined 35+ years of clinical, commercial, and regulatory experience in the development of these products. Their deep knowledge has put us at the forefront of new technologies as we work to aid patients by efficiently bringing leading-edge products to market. Our operational models are focused solely on the vascular space, providing the insights and methods needed to support complex product development. Over the years, our team of experts has demonstrated repeated editorial success among the landmark publications that aid in the advancement of treatments across a wide range of vascular diseases. These experts have also served as key innovators whose novel technologies have transformed the overall standard of care.
Vastrax的外部链接
US，Andover
Congratulations Charles Matouk Yale Department of Neurosurgery ??CereVasc ??
Congratulations to Dr. Charles Matouk and the Yale Department of Neurosurgery on their milestone 10th procedure in the US Pilot Study of the?CereVasc eShunt System in Normal Pressure Hydrocephalus!
Congratulations WallabyPhenox on PROST RCT trial - Raul Nogueira Ricardo Hanel Donald Lobsien
Final results from PROST have been published in JAMA Neurology, providing evidence that #thrombectomy with WallabyPhenox's Preset device is safe/effective in LVO #stroke, having shown non-inferiority to Medtronic's Solitaire. Nogueira Gomes Ricardo Hanel Donald Lobsien Medtronic Neurovascular
Vastrax转发了
Chief Clinical Officer, Emerging Neurotech Strategy, leading neuro clinical evidence and cutting-edge neurotech innovation ??
Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment A Randomized Clinical Trial WallabyPhenox #aneurysm